<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Family Reprod Health</journal-id><journal-id journal-id-type="iso-abbrev">J Family Reprod Health</journal-id><journal-id journal-id-type="publisher-id">JFRH</journal-id><journal-title-group><journal-title>Journal of Family &#x00026; Reproductive Health</journal-title></journal-title-group><issn pub-type="ppub">1735-8949</issn><issn pub-type="epub">1735-9392</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24971132</article-id><article-id pub-id-type="pmc">4064756</article-id><article-id pub-id-type="publisher-id">JFRH-8-041</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of Sublingual and Vaginal Misoprostol for Second-Trimester Pregnancy Terminations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Milani</surname><given-names>Forozan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sharami</surname><given-names>Seyede Hajar</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Arjmandi</surname><given-names>Saeedeh</given-names></name></contrib></contrib-group><aff>Reproductive Health Research center, Guilan university of Medical Sciences, Rasht, Iran</aff><author-notes><corresp id="cor1"><bold>Correspondence:</bold> Dr. Saeedeh Arjmandi, Reproductive Health Research Center, Department of Obstetrics and Gynecology, Alzahra Hospital, Rasht, Iran. Email: <email xlink:href="forozanmilani@yahoo.com">forozanmilani@yahoo.com</email>, <email xlink:href="H_fertility@gums.ac.ir">H_fertility@gums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2014</year></pub-date><volume>8</volume><issue>1</issue><fpage>41</fpage><lpage>44</lpage><history><date date-type="received"><month>3</month><year>2013</year></date><date date-type="rev-recd"><month>4</month><year>2013</year></date><date date-type="accepted"><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec id="st1"><title>Objective</title><p>Comparing sublingual and vaginal misoprostol in second trimester pregnancy termination.</p></sec><sec id="st2"><title>Materials and methods</title><p>In this study 268 women at 12-24 weeks of gestation candidate for pregnancy termination were enrolled. Women were randomly divided in two groups. The first group received 400 &#x000b5;g sublingual misoprostol and vaginal placebo and the second group received 400 &#x000b5;g vaginal misoprostol and sublingual placebo every 4 hours for a maximum of five doses. The course of misoprostol was repeated if the women did not abort within 24 hours.</p></sec><sec id="st3"><title>Results</title><p>The median induction-to-abortion interval was shorter in sublingual group (12/72 hours in sublingual and 14/67 hours in vaginal). There was no significant difference in the success rate at 24 and 48 hours and in side effects. The preference for the sublingual route of administration was higher.</p></sec><sec id="st4"><title>Conclusion</title><p>Both vaginal and sublingual misoprostol are effective for medical abortion in second trimester termination. But it appears from shorter induction interval in sublingual and higher acceptability that sublingual route is a better choice.</p></sec></abstract><kwd-group><kwd>Misoprostol</kwd><kwd>Vaginal</kwd><kwd>Sublingual</kwd><kwd>Second Trimester Termination</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Abortions during the second trimester represent only 10% to 15% of all induced abortions, but provoke two-thirds of all the serious complications and half of the deaths directlyrelated to this practice (<xref rid="CIT0001" ref-type="bibr">1</xref>). With the wide-scale introduction of prenatal screening programs, the issue of second trimester abortion has become increasingly relevant, in particular for women whose pregnancies are complicated by a serious fetal anomaly (<xref rid="CIT0002" ref-type="bibr">2</xref>). Prostaglandins and their analogues are widely used for medical Terminationof pregnancy. Misoprostol is a PGE1analogue available in a tablet form that is stable at room temperature and inexpensive (<xref rid="CIT0003" ref-type="bibr">3</xref>). Two common routes of misoprostol administration are sublingual and vaginal; but they have different pharmacokinetics and effectiveness. Sublingual misoprostol reaches its peak concentration in a short time due to rapid absorption and has higher bioavailability; the vaginal route causes more prolonged regular uterine contractions. The vaginal route has less adverse effects such as nausea, vomiting and diarrhea after administration (<xref rid="CIT0004" ref-type="bibr">4</xref>). Therefore in this paper we have compared the sublingual route to the vaginal route in the administration of misoprostol for second-trimester termination.</p></sec><sec sec-type="materials|methods" id="S0002"><title>Materials and methods</title><p>Our study is a double blinded randomized clinical trial that was performed in Alzahra hospital of Rasht (IRAN), from September 2012 to January 2013. The study was approved by the ethics committee of Guilan University of Medical Sciences. Informed consent was obtained from patients. Indications for second trimester termination were intra uterine fetal death, chromosomal abnormalities, fetal anomaly and legal abortion based on maternal reasons. Exclusion criteria were contraindications to prostaglandins use (bronchial asthma, cough, appearance of skin signs, glaucoma),women with previous uterine surgery and cesarean section, multiple pregnancies, parity &#x0003e; 3, vaginal bleeding and placenta previa. Totally 268 pregnant women (between 12 and 24 weeks) were admitted. Four cases from vaginal and four cases from sublingual group withdrew before the study (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). Neither the investigator nor the patients were blinded to the treatment group. Women were randomly assigned to group A and B(130 patients in each group). Group A was given 400 &#x000b5;g sublingual misoprostol and vaginal placebo and group B was given 400 &#x000b5;g vaginal misoprostol and sublingual placebo at 4 hours interval (maximum of five doses) in 24 hours. The desire outcome was fetus expulsion and if did not occur, the same regimen was repeated 24 hours after the start of the first dose of misoprostol. A structured form was used to record age, previous obstetrics history ( miscarriage, parity, gravidity), the time interval between misoprostol application and fetus expulsion, the number of tablets required, side effects such as fever, chills, diarrhea, nausea, vomiting, needing to analgesics and patient&#x02018;s preference on the routes of application. Analysis was done using the SPSS 16.0 statistical package. This study was done with financial support of Vice chancellor of research Guilan University of Medical Sciences.</p><fig id="F0001" position="float"><label>Fig. 1</label><caption><p>Flow chart for the progress through the trial</p></caption><graphic xlink:href="JFRH-8-041-g001"/></fig><sec id="S20003"><title>Statistical analysis</title><p>Data analysis was performed by using SPSS version16, All outcomes were assessed using Chi-squared test and independent t-test and mann-whitney. A level of 0.05 or less was considered significant.</p></sec></sec><sec sec-type="results" id="S0004"><title>Results</title><p>There was no statistically significant difference in women&#x02018;s basic characteristics such as age, gestational age, parity, number of miscarriages between the two groups (<xref ref-type="table" rid="T0001">Table 1</xref>). The mean maternal age was 30.28&#x000b1; 6.78 years in the vaginal group and 29.72&#x000b1; 6.45 years in the sublingual group (p= 0.457). The mean gestational age was 16.11&#x000b1; 2.64 in the vaginal group and 15.91&#x000b1; 2.8 in the sublingual group (p= 0.555). The success rate at 24 hours was 72% in the sublingual group and 76% in the vaginal group(p= 0.39). There was no statistically significant difference between the two groups (<xref ref-type="table" rid="T0002">Table 2</xref>) And the success rate of fetus expulsion did not differ in the two groups(81.5% in the vaginal group and 74.6% in the sublingual group, p= 0.177) (<xref ref-type="table" rid="T0002">Table 2</xref>). The median induction-to-fetus expulsion intervalwassignificantly shorter in the sublingual group (<xref ref-type="table" rid="T0002">Table 2</xref>).
</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Demographic characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1"/><th align="center" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1">Sublingual n (%)</th><th align="center" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1">Vaginal n (%)</th><th align="center" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">BMI</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; &#x0003c; 19</td><td align="center" rowspan="1" colspan="1">3(2.3)</td><td align="center" rowspan="1" colspan="1">2(1.5)</td><td align="center" rowspan="1" colspan="1">0.869</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;19-25</td><td align="center" rowspan="1" colspan="1">67(51.5)</td><td align="center" rowspan="1" colspan="1">62(47.7)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;25-30</td><td align="center" rowspan="1" colspan="1">49(37.7)</td><td align="center" rowspan="1" colspan="1">53(40.8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;30 &#x0003c;</td><td align="center" rowspan="1" colspan="1">11(8.5)</td><td align="center" rowspan="1" colspan="1">13(10)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" style="background-color: #e6eed5" rowspan="1">Previousabortion</td></tr><tr><td align="left" style="background-color: #e6eed5" rowspan="1" colspan="1">&#x02003;0</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">106(81.5)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">105(80.7)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">0.987</td></tr><tr><td align="left" style="background-color: #e6eed5" rowspan="1" colspan="1">&#x02003;1</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">22(16.9)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">23(17.7)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color: #e6eed5" rowspan="1" colspan="1">&#x02003;2 &#x02264;</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">2(1.5)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">2(1.5)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" rowspan="1">Parity</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">89(68.5)</td><td align="center" rowspan="1" colspan="1">87(66.9)</td><td align="center" rowspan="1" colspan="1">0.532</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td align="center" rowspan="1" colspan="1">25(19.2)</td><td align="center" rowspan="1" colspan="1">20(15.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td align="center" rowspan="1" colspan="1">16(12.3)</td><td align="center" rowspan="1" colspan="1">23(17.7)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color: #e6eed5" rowspan="1" colspan="1">Maternal age(years) (mean&#x000b1; SD)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">29.72&#x000b1; 6.45</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">30.28&#x000b1; 6.67</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">0.495</td></tr><tr><td align="left" rowspan="1" colspan="1">Gestational age(weeks) (mean&#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">15.91&#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">16.11&#x000b1; 2.64</td><td align="center" rowspan="1" colspan="1">0.555</td></tr></tbody></table></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Effectiveness of sublingual versus vaginal misoprostol for fetus expulsion</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1"/><th align="center" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1">Sublingual group n = 130</th><th align="center" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1">Vaginal group n = 130</th><th align="center" style="background-color: #4a6e62; color:white" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Success rate in 24 hours [n (%)]</td><td align="center" rowspan="1" colspan="1">94 (72.3)</td><td align="center" rowspan="1" colspan="1">100 (76.9)</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" style="background-color: #e6eed5" rowspan="1" colspan="1">Success rate in 48 hours [n (%)]</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">97 (74.6)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">106 (81.5)</td><td align="center" style="background-color: #e6eed5" rowspan="1" colspan="1">0.177</td></tr><tr><td align="left" rowspan="1" colspan="1">Induction to abortion period (hour) (mean&#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">12.72&#x000b1; 5.79</td><td align="center" rowspan="1" colspan="1">14.67&#x000b1; 6.16</td><td align="center" rowspan="1" colspan="1">0.22</td></tr></tbody></table></table-wrap><p>The mean dose applied was 1311.34 &#x000b5;g in the sublingual group and 1593.62 &#x000b5;g in the vaginal group that shows the sublingual group needed lower dose of misoprostol for fetus expulsion in comparison with the vaginal group (p= 0.010). Side effects such as fever, chills, nausea, vomiting, diarrhea, headache and needing to analgesics were compared and we found no significant difference in the two groups (p&#x0003e; 0.05). Totally 74.6% of the sublingual group and 25.4% of vaginal group preferred the sublingual route. No serious complication such as uterine rupture was reported in both groups.</p></sec><sec sec-type="discussion" id="S0005"><title>Discussion</title><p>Different studies were performed to compare sublingual versus vaginal misoprostol in second-trimester termination, but there were different results about the success rate of pregnancy termination in 24 hours, in 48 hours, the time interval between induction and fetus expulsion and the side effects in both groups.</p><p>In TANG ET AL study using 400 &#x000b5;g sublingual and vaginal misoprostol every 3 hours achieved similar success rate in 48 hours in both groups (&#x0003e;90%) but the success rate in 24 hours was significantly higher in the vaginal group (<xref rid="CIT0005" ref-type="bibr">5</xref>). But in our study no significant differences were seen in the success rate of fetus expulsion in 24 and 48 hours in both groups. Finally, TANG ET AL&#x02018;s study suggest that both routs of application are effective in second-trimester termination but, regarding to the side effects and patients acceptability, sublingual misoprostol is a better option.</p><p>Results of Delavari&#x02018;s study, that compared vaginal and sublingual routs by giving 400 &#x000b5;g misoprostol every 6 hours,reported that there were similar effects in second-trimester termination. The median induction to abortion period was 16 hours that is longer than our study(&#x0003c;15 hours) which is maybe due to longer interval between drugs application (<xref rid="CIT0004" ref-type="bibr">4</xref>).</p><p>Similar toBartusevicus&#x02018;s study (<xref rid="CIT0006" ref-type="bibr">6</xref>), our study demonstrated that induction to abortion period is significantly shorter in the sublingual group and this group needed lower dose of drug for abortion. It can be due to different pharmacokinetics profile of two routes. Because of absent intestinal-hepatic passage in vaginal application, it seems that drug activity and bioavailability is higher in vaginal route (<xref rid="CIT0007" ref-type="bibr">7</xref>&#x02013;<xref rid="CIT0010" ref-type="bibr">10</xref>),but one study that investigated pharmacokinetics of vaginal and sublingual misoprostol, demonstrated that maximum plasma concentration was higher in sublingual application (<xref rid="CIT0001" ref-type="bibr">1</xref>). Sublingual misoprostol can achievesthe higher peak concentration and bioavailability very quickly. Sustained and long-lasting effect is seen in vaginal absorption (<xref rid="CIT0007" ref-type="bibr">7</xref>&#x02013;<xref rid="CIT0009" ref-type="bibr">9</xref>), but the absorption is disturbed by local factors such as vaginal bleeding (<xref rid="CIT0007" ref-type="bibr">7</xref>).</p><p>Some previous studies suggested that side effects such as fever, chills, diarrhea and vomiting are more common whit the sublingual route of administration(<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0011" ref-type="bibr">11</xref>),but our study was not supported these findings. In our study, similar to Von Hertzen H&#x02018;s study (<xref rid="CIT0012" ref-type="bibr">12</xref>), the side effects were comparable in the two groups.</p><p>It seems that sublingual administration is a more preferable way of giving misoprostol (<xref rid="CIT0013" ref-type="bibr">13</xref>&#x02013;<xref rid="CIT0015" ref-type="bibr">15</xref>). In our study,all patients experienced both vaginal and sublingual routes(misoprostol and placebo) and higher percentage of women preferred the sublingual route (74.6% versus 25.4%). The sublingual route appears to be more convenient and less uncomfortable.</p><p>This study concludes although both vaginal and sublingual routes have similar effectiveness and side effects in second-trimester termination, but sublingual route is a better option because of its quicker response and better acceptability.</p></sec></body><back><ack><title>Acknowledgements</title><p>This investigation was based on a thesis submitted by the third author to the Guilan University of Medical Sciences. This study was done with financial support provided by Vice Chancellor of Research Center of Guilan University of Medical Sciences. There is no conflict of interest in this study.</p></ack><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname><given-names>Y</given-names></name><name><surname>Fern&#x000e1;ndez-Guisasola</surname><given-names>J</given-names></name><name><surname>Lobo</surname><given-names>P</given-names></name><name><surname>G&#x000e1;mir</surname><given-names>S</given-names></name><name><surname>Alvarez</surname><given-names>J</given-names></name></person-group><article-title>Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: A meta-analysis</article-title><source>Aust N Z J ObstetGynaecol</source><year>2011</year><volume>51</volume><fpage>158</fpage><lpage>65</lpage></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildschut</surname><given-names>H</given-names></name><name><surname>Both</surname><given-names>MI</given-names></name><name><surname>Medema</surname><given-names>S</given-names></name><name><surname>Thomee</surname><given-names>E</given-names></name><name><surname>Wildhagen</surname><given-names>MF</given-names></name><name><surname>Kapp</surname><given-names>N</given-names></name></person-group><article-title>Medical methods for mid-trimester termination of pregnancy</article-title><source>Cochrane Database Syst Rev</source><year>2011</year><volume>19</volume><fpage>CD005216</fpage><pub-id pub-id-type="pmid">21249669</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>PC</given-names></name><name><surname>Blumenthal</surname><given-names>PD</given-names></name><name><surname>Gemzell-Danielsson</surname><given-names>K</given-names></name><name><surname>G&#x000f3;mez Ponce de Le&#x000f3;n</surname><given-names>R</given-names></name><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>OS</given-names></name></person-group><article-title>Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks</article-title><source>Int J GynaecolObstet</source><year>2007</year><volume>99</volume><issue>Suppl 2</issue><fpage>S178</fpage><lpage>81</lpage></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanha</surname><given-names>FD</given-names></name><name><surname>Golgachi</surname><given-names>T</given-names></name><name><surname>Niroomand</surname><given-names>N</given-names></name><name><surname>Ghajarzadeh</surname><given-names>M</given-names></name><name><surname>Nasr</surname><given-names>R</given-names></name></person-group><article-title>Sublingual versus vaginal misoprostol for second trimester termination: a randomized clinical trial</article-title><source>Arch GynecolObstet</source><year>2013</year><volume>287</volume><fpage>65</fpage><lpage>9</lpage></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>OS</given-names></name><name><surname>Lau</surname><given-names>WN</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>A prospectiverandomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy</article-title><source>BJOG</source><year>2004</year><volume>111</volume><fpage>1001</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15327617</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartusevicius</surname><given-names>A</given-names></name><name><surname>Barcaite</surname><given-names>E</given-names></name><name><surname>Nadisauskiene</surname><given-names>R</given-names></name></person-group><article-title>Oral, Vaginal and sublingual misoprostol for induction of labor</article-title><source>Int J Gynaecol Obstet</source><year>2005</year><volume>91</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16109419</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>OS</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation</article-title><source>Hum Reprod</source><year>2002</year><volume>17</volume><fpage>1738</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12093832</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>OS</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>Pilot study on the use of sublingualmisoprostol for medical abortion</article-title><source>Contraception.</source><year>2001</year><volume>64</volume><fpage>315</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11777493</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>N</given-names></name><name><surname>Saha</surname><given-names>SP</given-names></name><name><surname>Ghoshroy</surname><given-names>SC</given-names></name><name><surname>Bhowmik</surname><given-names>S</given-names></name><name><surname>Barui</surname><given-names>G</given-names></name></person-group><article-title>Arandomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy</article-title><source>Aust N Z J ObstetGynaecol</source><year>2008</year><volume>48</volume><fpage>165</fpage><lpage>71</lpage></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Salhan</surname><given-names>S</given-names></name><name><surname>Sarda</surname><given-names>N</given-names></name></person-group><article-title>Comparison between the sublingual and oral route of misoprostol for pre-abortion cervical priming in first trimester abortions</article-title><source>Hum Reprod</source><year>2004</year><volume>19</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">14688160</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>OS</given-names></name><name><surname>Gemzell-Danielsson</surname><given-names>K</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects</article-title><source>Int J GynaecolObstet</source><year>2007</year><volume>99</volume><issue>Suppl 2</issue><fpage>S160</fpage><lpage>7</lpage></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Hertzen</surname><given-names>H</given-names></name><name><surname>Piaggio</surname><given-names>G</given-names></name><name><surname>Wojdyla</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>TM</given-names></name><name><surname>Marions</surname><given-names>L</given-names></name><name><surname>Okoev</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial</article-title><source>Hum Reprod</source><year>2009</year><volume>24</volume><fpage>106</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18794161</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>OS</given-names></name><name><surname>Lau</surname><given-names>WN</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>A prospectiverandomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy</article-title><source>BJOG</source><year>2004</year><volume>111</volume><fpage>1001</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15327617</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Salhan</surname><given-names>S</given-names></name><name><surname>Sarda</surname><given-names>N</given-names></name></person-group><article-title>Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy</article-title><source>Contraception</source><year>2003</year><volume>67</volume><fpage>213</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12618256</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Fong</surname><given-names>YF</given-names></name><name><surname>Prasad</surname><given-names>RN</given-names></name><name><surname>Dong</surname><given-names>F</given-names></name></person-group><article-title>Does an acidic medium enhance the efficacy of vaginalmisoprostolfor pre-abortion cervical priming?</article-title><source>Hum Reprod</source><year>1999</year><volume>14</volume><fpage>1635</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10357990</pub-id></element-citation></ref></ref-list></back></article>